ProQR Therapeutics N.V. (PRQR) Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets

ProQR Therapeutics N.V. Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets

ProQR Therapeutics N.V. (PRQR) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of EUR 4.01 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-12.

Financial Statements › Expense Statement › Operating Expenses

ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2026-03-12

• ProQR Therapeutics N.V. expense from equitysettled share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2025-12-31 was 1.23M EUR, a 116.55% increase year-over-year.
• ProQR Therapeutics N.V. expense from equitysettled share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2025-09-30 was 1.12M EUR, a 82.52% increase year-over-year.
• ProQR Therapeutics N.V. expense from equitysettled share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2025-06-30 was 909.00K EUR, a 44.75% increase year-over-year.
• ProQR Therapeutics N.V. expense from equitysettled share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2025-03-31 was 758.00K EUR, a 2.99% increase year-over-year.